US2021346296A1PendingUtilityA1

A biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same

Assignee: M TECHNIQUE CO LTDPriority: May 8, 2020Filed: May 8, 2020Published: Nov 11, 2021
Est. expiryMay 8, 2040(~13.8 yrs left)· nominal 20-yr term from priority
A61K 31/10A61K 9/1647A61K 9/0024A61K 31/57A61K 45/06C08J 3/12A61K 9/5026A61K 9/5031A61K 9/5047A61K 9/5089C08J 2329/04C08J 2367/04C08J 2429/04C08J 2467/04C08K 5/07C08K 5/132A61K 9/1641A61K 31/095A61K 31/12A61K 31/496A61K 31/7048A61K 9/1652
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application provides a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) as a main component, in which a biologically active substance is uniformly dispersed, wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less, and a mass of the biologically active substance or an empty hole of 1.5 μm or more is not present in the microsphere. The microsphere of the present invention can appropriately control the initial release amount of the biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time.

Claims

exact text as granted — not AI-modified
1 . A microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) as a main component,
 wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less,   a biologically active substance is uniformly dispersed inside the microsphere, and   a mass of the biologically active substance or an empty hole of 1.5 μm or more is not observed inside the microsphere, in an electron microscope image of a cross section of the microsphere.   
     
     
         2 . The microsphere according to  claim 1 , wherein a mass of the biologically active substance or an empty hole of 1.0 μm or more is not observed inside the microsphere. 
     
     
         3 . The microsphere according to  claim 1 , wherein an average volume-based particle diameter of the dispersed biologically active substance is 5 nm to 500 nm. 
     
     
         4 . The microsphere according to  claim 1 , wherein the biologically active substance is a lipophilic biologically active substance. 
     
     
         5 . A sustained release formulation comprising the microsphere according to  claim 1 . 
     
     
         6 . A sustained release formulation comprising the microsphere according to  claim 2 . 
     
     
         7 . A sustained release formulation comprising the microsphere according to  claim 3 . 
     
     
         8 . A sustained release formulation comprising the microsphere according to  claim 4 .

Join the waitlist — get patent alerts

Track US2021346296A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.